Biovail Announces Its Appeal to District Court Decisions.

Business Editors, Health & Medical Writers

TORONTO--(BW HealthWire)--March 8, 2000

Biovail Corporation ("Biovail") (NYSE:BVF)(TSE:BVF) announced today that it has launched an appeal to the decision released earlier today by the United States District Court of the Southern District of Florida which found that Andrx Pharmaceutical's formulation of a generic version of Tiazac(R) does not infringe Tiazac(R)'s patent. Biovail's position is that Andrx' formulation clearly infringes Biovail's patent. Biovail has launched an appeal of that decision. Biovail is confident of its legal position and expects the Court of Appeals to overturn the District Court's finding(s).

The court also found, however, that Biovail's Tiazac(R) patent is valid and therefore rejected Andrx' claim of invalidity.

Biovail expects that if and when Andrx receives tentative FDA approval, the FDA will not grant final approval to Andrx, thus precluding Andrx from marketing its product, until the Waxman Hatch thirty-month stay has elapsed (February 2001) or a final decision of the Court of Appeals is released, whichever occurs earlier.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of producing FDA and TPP approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission.